ライフサイエンスコーパス: cervicovaginal

1 macaques have a cyclical pattern of changing cervicovaginal Ab and immunoglobulin levels that is simi

2 S) in utero develop abnormalities, including cervicovaginal adenosis that can lead to cancer.

3 Five hundred consecutive cervicovaginal and anorectal specimens submitted for GBS

4 Amerindian cervicovaginal and introital microbiota diversity were n

5 Among all women, cervicovaginal and introital samples clustered, respecti

6 characterized the vaginal microbiota in the cervicovaginal and introital sites in sexually active Am

7 ted atazanavir (ATV) underwent serial paired cervicovaginal and plasma sampling for antiretroviral co

8 ained below the estimates for self-collected cervicovaginal and provider-collected cervical samples (

9 p cultures of human tonsils, lymph nodes and cervicovaginal and rectosigmoid tissues, including proto

10 screened for cervicovaginal HSV-2 DNA, GUD, cervicovaginal and systemic HIV-1 RNA, and reproductive

11 collected daily genital swabs of the vulvar, cervicovaginal, and perianal areas for HSV culture, main

12 lts and triple-matched urine, self-collected cervicovaginal, and provider-collected cervical hrHPV re

13 Humoral and cervicovaginal antibodies reacting to MgpB were induced

14 different HPV serotypes induced 10-fold more cervicovaginal antigen-specific CD8+ T cells than primin

15 Cervicovaginal bacteria modulate genital inflammation; h

16 virions initially bind preferentially to the cervicovaginal basement membrane (BM) at sites of trauma

17 Cervicovaginal CD4+ T cells are preferential targets for

18 agonists to recruit and increase the pool of cervicovaginal CD8(+) T(RM) Transient Ag presentation in

19 atforms for inducing durable intraepithelial cervicovaginal CD8+ T cell responses by promoting local

20 ectively, were cloned and characterized from cervicovaginal cells by use of an overlapping PCR method

21 Exfoliated cervicovaginal cells from 19 of 54 animals tested positi

22 ages of HPV16 were cloned and sequenced from cervicovaginal cells.

23 association can occur in vivo in the murine cervicovaginal challenge model of HPV16 infection.

24 Using a recently developed murine cervicovaginal challenge model, we evaluated the importa

25 to gonococcal infection in a murine model of cervicovaginal colonization and identified MisR-regulate

26 ssue drug exposure through modulation of the cervicovaginal, colorectal, or immune cell transporters.

27 cases, the frequency of this response in the cervicovaginal compartment far exceeded the frequency in

28 influence genital inflammation by comparing cervicovaginal cytokine changes following contraception

29 Although Cu-IUD use broadly increased cervicovaginal cytokine concentrations at 6 months posti

30 Cervicovaginal cytokine concentrations did not differ be

31 Here we explored the role of cervicovaginal cytokines and drug metabolizing enzymes a

32 Cervicovaginal cytokines were quantified from menstrual

33 nd LNG-implant did not experience changes in cervicovaginal cytokines.

34 In the cervicovaginal environment, human papillomavirus (HPV) a

35 well as results from in vitro activation of cervicovaginal epithelial cells and U1/HIV promonocytic

36 However, some cervicovaginal epithelial cells failed to express p63, r

37 36G expression was significantly elevated in cervicovaginal epithelial cells isolated from BV-positiv

38 bitory effect of DES was transient, and most cervicovaginal epithelial cells recovered expression of

39 and that conditioned medium from GC-exposed cervicovaginal epithelial cells with elevated levels of

40 Here we report interactions of human cervicovaginal epithelial cells with the most abundant c

41 In p63(-/-) mice, cervicovaginal epithelium differentiated into uterine ep

42 usculus), can cause infections in the female cervicovaginal epithelium of immunocompetent mice that p

43 epithelium of the progesterone group and the cervicovaginal epithelium of the combination group.

44 tal day 1 to 5 inhibited induction of p63 in cervicovaginal epithelium via epithelial ERalpha.

45 seminal plasma (SP), rectal fluid (RF), and cervicovaginal fluid (CVF) at baseline, at days 3, 7, 14

46 seminal plasma (SP), rectal fluid (RF), and cervicovaginal fluid (CVF) at baseline; Days 3, 7, 14, a

47 with BVAB (endocervical+BVAB CM), as well as cervicovaginal fluid (CVF) from women with BV, disrupted

48 ar cell-associated blood HIV-1 DNA load, and cervicovaginal fluid (CVF) HIV-1 DNA load were determine

49 ation of longitudinal vaginal microbiota and cervicovaginal fluid (CVF) immunophenotype data collecte

50 Human cervicovaginal fluid (CVF) is a complex, functionally im

51 l elastase (HNE) were measured in over 1,000 cervicovaginal fluid (CVF) samples (10 to 24 weeks' gest

52 rug concentrations were evaluated in plasma, cervicovaginal fluid (CVF), and cervical tissue samples.

53 seminal plasma (SP), rectal tissue (RT), and cervicovaginal fluid (CVF).

54 Cytokines were measured in cervicovaginal fluid (CVF).

55 Anti-MVA IgG and IgA were detected in cervicovaginal fluid after a second vaccine dose.

56 Cervicovaginal fluid and cervical biopsies were collecte

57 Appropriate clinical sampling devices for cervicovaginal fluid collection would help physicians de

58 We compared changes over time in cervicovaginal fluid cytokine and chemokine concentratio

59 ed to develop an effective device to collect cervicovaginal fluid from women with symptoms of endomet

60 Cervicovaginal fluid plays an important role in the dete

61 Detection of SLPs within cervicovaginal fluid samples is associated with decrease

62 Cervicovaginal fluid tenofovir concentrations did not di

63 The estimated median volume of cervicovaginal fluid was 0.51 ml (interquartile range, 0

64 llected for measuring the HIV-1 RNA level in cervicovaginal fluid, phosphate-buffered saline containi

65 xil fumarate and tenofovir concentrations in cervicovaginal fluid, tenofovir in plasma, and tenofovir

66 ion stimulated by HLA antigens in seminal or cervicovaginal fluid.

67 and activity of bacterial and human GDEs in cervicovaginal fluid.

68 ons were observed in both seminal plasma and cervicovaginal fluid.

69 inner cotton portion was designed to absorb cervicovaginal fluid.

70 ssfully used the developed device to collect cervicovaginal fluid.

71 ADCC antibodies are present in the cervicovaginal fluids, which indicates that this form of

72 ells, isolated immune cells, and analyses of cervicovaginal fluids.

73 Rather, cervicovaginal HA plays an unanticipated important role

74 They are active ex vivo in human cervicovaginal histocultures infected by HSV-2 and in vi

75 clovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% con

76 Cervicovaginal HIV-1 RNA and herpes simplex virus type 2

77 0.8-1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (-0.06 log(10) copies/mL;

78 Here, we evaluate for cervicovaginal HIV-neutralizing IgA responses in genital

79 -specific VE correlated well with VE against cervicovaginal HPV (Spearman rho = 0.76), suggesting com

80 16 IgA was associated with sexual behavior, cervicovaginal HPV 16 DNA, and cytological abnormalities

81 women, previously tested for the presence of cervicovaginal HPV DNA, were analyzed.

82 evels (continuous and categorical forms) and cervicovaginal HPV infection (due to high-risk HPV or va

83 have been shown to be at increased risk for cervicovaginal HPV infection and CIN, and cervical cance

84 total of 2353 sexually active women for whom cervicovaginal HPV infection status and serum 25-hydroxy

85 clinical serum samples from women with known cervicovaginal HPV infection status.

86 Cervicovaginal HPV prevalence is associated with less-th

87 Cervicovaginal HPV testing is 90% sensitive for detectin

88 e most sensitive method for the detection of cervicovaginal HPV.

89 The peptide also inhibits cervicovaginal HPV16 pseudovirus infection in a mouse mo

90 The seroprevalences of IgG in women with cervicovaginal HPV16, HPV16-related types, and other HPV

91 nal HIV-1 RNA (RR, 0.70; 95% CI, 0.4-1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4-1.3), ha

92 c therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer hea

93 study was to assess factors associated with cervicovaginal HSV-2 DNA shedding and genital ulcer dise

94 Cervicovaginal HSV-2 DNA was detected in 42% of women (9

95 Participants were screened for cervicovaginal HSV-2 DNA, GUD, cervicovaginal and system

96 RT is strongly associated with a decrease in cervicovaginal HSV-2 shedding, and the impact was sustai

97 ious diseases; however, its association with cervicovaginal human papillomavirus (HPV) infection has

98 Risk factors for cervicovaginal human papillomavirus (HPV) infection were

99 submicromolar range in ex vivo lymphoid and cervicovaginal human tissues and at 3-12 micromol/L in C

100 We evaluated cervicovaginal IgA in Partners PrEP Study participants u

101 The relationship between vaccine and cervicovaginal IgG achieved significance (odds ratio [OR

102 Cervicovaginal immune mediator concentrations were highe

103 y concentration required for protection from cervicovaginal infection is comparable to that required

104 e report the development of a mouse model of cervicovaginal infection with HPV16 that recapitulates t

105 re susceptible to a transient papillomavirus cervicovaginal infection, and mice deficient in select g

106 ciation was lost after adjustment for HPV 16 cervicovaginal infection.

107 third of the female recipient mice acquired cervicovaginal infections.

108 oncomitant lower genital-tract infections on cervicovaginal inflammatory cells was assessed in 967 wo

109 age, and race have an independent effect on cervicovaginal inflammatory cells.

110 Cervicovaginal inflammatory cytokine concentrations were

111 votella bivia) were strongly associated with cervicovaginal inflammatory cytokines, but not with alte

112 helium to be columnar (uterine) or squamous (cervicovaginal) is determined by mesenchymal induction d

113 , respiratory syncytial virus (RSV) M/M2, in cervicovaginal keratinocytes.

114 Thus, while cervicovaginal lactobacilli reduced the production of th

115 Twenty-four couples were enrolled; cervicovaginal lavage (CVL) and tissue were collected 2

116 ducted to analyze the presence of HCV RNA in cervicovaginal lavage (CVL) fluid from 71 women (58 HCV/

117 ty (CMI) was evaluated for the first time in cervicovaginal lavage (CVL) fluid from RVVC patients.

118 sence of a heat-stable soluble factor in the cervicovaginal lavage (CVL) fluid of both HIV-infected a

119 Cervicovaginal lavage (CVL) fluid was evaluated for tota

120 ory cytokine concentrations were measured in cervicovaginal lavage (CVL) from 49 women 6, 17, 30, and

121 mbled full-length HIV-1 genomes from matched cervicovaginal lavage (CVL) samples and plasma.

122 igned to determine the antiviral activity in cervicovaginal lavage (CVL) samples collected after intr

123 tic cells secreted TNF- alpha in response to cervicovaginal lavage (CVL) samples from women with BV.

124 ng into the genital tract, paired plasma and cervicovaginal lavage (CVL) samples were obtained from 1

125 Cervicovaginal lavage (CVL) samples were obtained from 2

126 nerella vaginalis, and Mycoplasma hominis in cervicovaginal lavage (CVL) samples were quantified by p

127 he Women's Interagency HIV Study contributed cervicovaginal lavage (CVL) samples.

128 pothesis-generating study, 17 women provided cervicovaginal lavage (CVL) specimens at baseline (all h

129 irus (CMV) was studied in blood, saliva, and cervicovaginal lavage (CVL) specimens from 33 HIV-1-infe

130 Abbott RealTime HIV-1 assay using plasma and cervicovaginal lavage (CVL) specimens.

131 formalin-fixed-tissue specimens collected by cervicovaginal lavage (CVL) within 90 days of each other

132 Microbiomes were characterized in cervicovaginal lavage and penile meatal swab through hig

133 Cervicovaginal lavage and plasma from 122 HIV-uninfected

134 ysis of 16S ribosomal RNA gene sequencing of cervicovaginal lavage clustered each participant visit i

135 HIV-RNA remained <50 copies/mL had sperm or cervicovaginal lavage collected between Weeks 24 and 48.

136 in plasma, female reproductive tract tissue, cervicovaginal lavage fluid and its intracellular metabo

137 and innate resistance) was also detected in cervicovaginal lavage fluid from both species.

138 Among the 27 cytokines analyzed in cervicovaginal lavage fluid from women in this village,

139 rrent quantified HIV-1 RNA concentrations in cervicovaginal lavage fluid in 301 women infected with t

140 n the cervical mucosa and cytokine levels in cervicovaginal lavage fluid.

141 Testing cervicovaginal lavage fluids for >40 HPV genotypes using

142 p160-specific IgA responses were detected in cervicovaginal lavage fluids in 6 of 13 HEPS CSWs but 0

143 nd prevalence of human papillomavirus DNA in cervicovaginal lavage fluids were all >50% and were 2-30

144 endocervical swabs were more sensitive than cervicovaginal lavage for HIV-1 RNA detection by PCR but

145 d in the plasma of 2 women and in at least 1 cervicovaginal lavage sample from all 6 women.

146 Cervicovaginal lavage samples (n = 19) were collected, c

147 s and proviral DNA in cervical, vaginal, and cervicovaginal lavage samples by polymerase chain reacti

148 + (GP+-PCR), for the detection of HPV DNA in cervicovaginal lavage samples from 208 women.

149 nerella vaginalis, and Mycoplasma hominis in cervicovaginal lavage samples were quantified by PCR.

150 In an analysis of 95 cervicovaginal lavage samples, we found that 12 (12.6%)

151 5) ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples.

152 ens from endocervical canal wick and most in cervicovaginal lavage samples.

153 Cervicovaginal lavage sequencing (n = 109) resulted in a

154 ty-two cytokines were measured by Luminex in cervicovaginal lavage specimens at enrollment.

155 al neoplasia grade 3 and cancer (CIN3+) with cervicovaginal lavage specimens collected at enrollment

156 Cervicovaginal lavage specimens from enrollment were tes

157 NA testing were conducted annually in serial cervicovaginal lavage specimens obtained over 8-10 years

158 land (of whom 184 were HIV+), provided 1,426 cervicovaginal lavage specimens tested for HPV DNA by a

159 Antenatal cervicovaginal lavage specimens were assessed for HIV-1

160 Cervicovaginal lavage specimens were collected from each

161 When cervicovaginal lavage specimens, the reverse line-blot a

162 09/11 system was evaluated with a set of 262 cervicovaginal lavage specimens.

163 were used to characterize HPV-16-containing cervicovaginal lavage specimens.

164 w ProTalpha variants from CD8(+) T cells and cervicovaginal lavage with potent anti-HIV-1 activity.

165 Schistosoma PCR was done on urine, biopsy, cervicovaginal lavage, and genital mucosal surface speci

166 Gingival, cervicovaginal lavage, and plasma specimens were collect

167 wicks should be considered as an adjunct to cervicovaginal lavage, to improve the sensitivity and pr

168 py and tests for human papillomavirus DNA in cervicovaginal lavage-for a median follow-up of 3.2 year

169 shes and from the ectocervix and vagina with cervicovaginal lavage.

170 HSV-2 DNA and HIV-1 RNA were quantified in cervicovaginal lavage.

171 t lifestyle and sexual behavior and obtained cervicovaginal-lavage samples for the detection of HPV D

172 ines were measured prior to HIV infection in cervicovaginal lavages (CVL) from 66 HIV seroconverters

173 y, and inflammatory cells were quantified in cervicovaginal lavages (CVLs) of 24 women enrolled in th

174 HIV DNA was detected in 6/13 (46%) DS cervicovaginal lavages at low levels.

175 Cervicovaginal lavages collected from 19,512 women atten

176 Cervicovaginal lavages from 34 women who did (n = 17) or

177 L-10 were measured prior to HIV infection in cervicovaginal lavages from 58 HIV seroconverters and 58

178 tryptophan, indole, and IFN-gamma levels in cervicovaginal lavages from women with either naturally

179 [RLU/PC]) using Hybrid Capture 2 testing of cervicovaginal lavages obtained at enrolment.

180 munoglobulins G and A and some antibodies in cervicovaginal lavages varied with the stages of the men

181 ted in 24/82 (29%) participants: 13/253 (5%) cervicovaginal lavages, 20/322 (6%) seminal plasmas, and

182 ADCC mediated by antibodies present in sera, cervicovaginal lavages, and breast milk from HIV-1-infec

183 blot analysis, secreted HD-5 was detected in cervicovaginal lavages, with the highest concentrations

184 [P=.01]) but was weakened by the presence of cervicovaginal leukocytes.

185 Cervicovaginal mesenchyme induced p63 in Mullerian duct

186 ple preparation-free characterisation of the cervicovaginal metabolome in two independent pregnancy c

187 In contrast to the gut, cervicovaginal microbe-binding IgA and IgG do not appear

188 These studies suggest that members of the cervicovaginal microbiome can modify N. gonorrhoeae, whi

189 Although cervicovaginal microbiome has been associated with cervi

190 Despite the importance of the cervicovaginal microbiome, the mechanisms that govern it

191 eveloping, ovarian cancer have an imbalanced cervicovaginal microbiome.

192 Increasing evidence suggests that the cervicovaginal microbiota (CVM) plays an important role

193 likely result from interactions between the cervicovaginal microbiota and host immune responses.

194 n BRCA1 status and ovarian cancer status and cervicovaginal microbiota community type, using a logist

195 A non-optimal cervicovaginal microbiota confers increased risk of sPTB

196 Our study proposes a mechanism by which cervicovaginal microbiota impact genital inflammation an

197 n-2 lowered the risk of sPTB associated with cervicovaginal microbiota in an ethnicity-dependent mann

198 The cervicovaginal microbiota of 51 participants were compos

199 We molecularly assessed the cervicovaginal microbiota over time in human immunodefic

200 Non-optimal cervicovaginal microbiota, characterized by depletion of

201 singly, even in Lactobacillus spp. dominated cervicovaginal microbiota, low beta-defensin-2 was assoc

202 Using innovative Bayesian modeling of cervicovaginal microbiota, seven bacterial taxa were sig

203 ation of a protective low vaginal pH, in the cervicovaginal microbiota.

204 ly associated with having a community type O cervicovaginal microbiota.

205 enesis; however, other features of the local cervicovaginal microenvironment (CVM) may play a critica

206 datasets to develop predictive models of the cervicovaginal microenvironment and identify characteris

207 uggests that host-microbe interaction in the cervicovaginal microenvironment contributes to cervical

208 is consistent with hypotheses that the local cervicovaginal milieu plays a role in susceptibility to

209 ed CD8+ T cell responses in the female mouse cervicovaginal mucosa after intravaginal immunization wi

210 duction of innate antiviral responses in the cervicovaginal mucosa by topical application of TLR agon

211 The intact cervicovaginal mucosa is a relative barrier to the sexua

212 nd other antiviral effector molecules in the cervicovaginal mucosa of treated animals.

213 Soluble factors from CD8(+) T cells and cervicovaginal mucosa of women are recognized as importa

214 the primed CD8+ T cells proliferated in the cervicovaginal mucosa upon HPV intravaginal boost.

215 with IFNepsilon expression) and FoxP3 in the cervicovaginal mucosa, and increased infiltration of CD4

216 ts for SIV were in the lamina propria of the cervicovaginal mucosa, immediately subjacent to the epit

217 ss the HIV-1 coreceptor CCR5 in normal human cervicovaginal mucosa, whereas all three cell types expr

218 d proinflammatory cytokine expression in the cervicovaginal mucosa.

219 after a single atraumatic application to the cervicovaginal mucosa.

220 fibers (pore sizes) in fresh undiluted human cervicovaginal mucus (CVM) obtained from volunteers with

221 Here, we report that human cervicovaginal mucus (CVM), obtained from donors with no

222 tibodies (Ab) can trap individual virions in cervicovaginal mucus (CVM), thereby reducing infection i

223 In fresh undiluted human cervicovaginal mucus (CVM), which has a bulk viscosity a

224 lants, and within two minutes in fresh human cervicovaginal mucus ex vivo.

225 coelastic human mucus, such as non-ovulatory cervicovaginal mucus, at a significant rate.

226 (PLGA) nanoparticles rapidly penetrate human cervicovaginal mucus, whereas PLGA nanoparticles coated

227 urface chemistries in samples of fresh human cervicovaginal mucus.

228 he transport of nanoparticles in fresh human cervicovaginal mucus.

229 We have developed human cervicovaginal organ culture systems to examine the init

230 Cervicovaginal:plasma antiretroviral concentration ratio

231 A cervicovaginal sample for the WID-qEC test was obtained

232 results for urine samples and self-collected cervicovaginal samples (kappa = 0.58) or provider-collec

233 sterdam, the Netherlands, and analyzed their cervicovaginal samples and clinical data.

234 tration and viscoelastic properties of these cervicovaginal samples are similar to those in many othe

235 ith suppressed plasma virus loads, blood and cervicovaginal samples collected twice weekly for 3 week

236 (hrHPV) testing of self-collected urine and cervicovaginal samples for the detection of cervical int

237 ction by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vacc

238 In 2010-2014, cervicovaginal samples from vaccinated and unvaccinated

239 Cervicovaginal samples were collected at baseline, cross

240 Cervicovaginal samples were gathered from all participan

241 Eleven cervicovaginal samples were tested at the point of care

242 ollected cervical samples and self-collected cervicovaginal samples, first-void urine is emerging as

243 Urine samples, self-collected cervicovaginal samples, provider-collected cervical samp

244 All underwent cervicovaginal sampling and Pap testing at regular inter

245 Subjects underwent cervicovaginal sampling and Pap testing on day 1 and the

246 l collection device and medium were used for cervicovaginal sampling.

247 nce of human immunodeficiency virus (HIV) in cervicovaginal secretions (CVS) may be a risk factor for

248 ted with human CD4+ cells that are shed into cervicovaginal secretions (CVS).

249 Cervicovaginal secretions and endocervical cells were co

250 nuclear cells and SIV-specific antibodies in cervicovaginal secretions at the time of challenge was a

251 These findings are evidence that cervicovaginal secretions contribute to innate resistanc

252 Cervicovaginal secretions from 86 Kenyan women, includin

253 rving the innate antiviral activity found in cervicovaginal secretions is critical.

254 specific antibodies were not detected in the cervicovaginal secretions of 10 STV monkeys examined.

255 quantify microbe-binding IgA and IgG in the cervicovaginal secretions of 200 HIV-uninfected women fr

256 ections have levels of sialidases present in cervicovaginal secretions that can result in desialylati

257 e cervix and assays for fetal fibronectin in cervicovaginal secretions, also had low sensitivity and

258 ysis of molecular and cellular components in cervicovaginal secretions, as well as results from in vi

259 ular, as well as other bodily fluids such as cervicovaginal secretions, could increase oral transmiss

260 IgA and IgG Abs in mucosal secretions (e.g., cervicovaginal secretions, rectal washes, and saliva) an

261 eutralizing antibodies also were observed in cervicovaginal secretions.

262 Cervicovaginal shedding was detected in 8 (4.4%) CMV-pos

263 Depressed cervicovaginal SLPI levels have been correlated with bot

264 ews; physical examination; blood, urine, and cervicovaginal specimen collection and repository; labor

265 For both cervicovaginal specimens (clinician collected and self-c

266 tween clinician-collected and self-collected cervicovaginal specimens (P > 0.01 for all comparisons).

267 zed HPV DNA types detected in self-collected cervicovaginal specimens and demographic, sexual behavio

268 ecovered throughout the 8-week experiment in cervicovaginal specimens and up to 2 weeks postinfection

269 ssays by each method were performed with 596 cervicovaginal specimens collected from participants in

270 haracterize the bacteriome and virome in 125 cervicovaginal specimens collected over two years from 3

271 d HSV-2 present in more than 60,000 clinical cervicovaginal specimens derived from samples originatin

272 Thus, use of HC2 on cervicovaginal specimens for screening could result in f

273 eptible leukocytes on female genital mucosa, cervicovaginal specimens from 32 HIV-negative STD clinic

274 Using data and self-collected cervicovaginal specimens from 4150 females, 14-59 years

275 of carcinogenic human papillomavirus DNA in cervicovaginal specimens self-collected using a novel de

276 cervicovaginal specimens, and self-collected cervicovaginal specimens taken at home.

277 cted cervical specimens, clinician-collected cervicovaginal specimens, and self-collected cervicovagi

278 Thirty-eight women provided 275 cervicovaginal specimens.

279 ly localize within rectal lamina propria and cervicovaginal stroma, with limited and variable epithel

280 determined by the Linear Array HPV Assay in cervicovaginal swab samples from females aged 14-59 year

281 females aged 14-59 years who self-collected cervicovaginal swab specimens.

282 dida species-specific PCR tests performed on cervicovaginal swabs over a 4-year period demonstrated c

283 Cervicovaginal swabs, which were used to measure bacteri

284 CCR5 expression, and cytokine production of cervicovaginal T cells in up to 16 donors.

285 Cervicovaginal Th17-related cytokines were measured by L

286 Using a cervicovaginal tissue culture system, we found that expr

287 cells and macrophages in vitro, in polarized cervicovaginal tissue explants, and in the female genita

288 by examining mononuclear cells obtained from cervicovaginal tissue, the mechanisms whereby HIV type 1

289 integration in organotypic cultures of human cervicovaginal tissue.

290 e phenotype of MAIT cells residing in paired cervicovaginal tissue.

291 We documented robust responses in cervicovaginal tissues and uterus, but only several days

292 osal barrier greatly limits the infection of cervicovaginal tissues, and thus the initial founder pop

293 els of GBS interaction with the human female cervicovaginal tract using human vaginal and cervical ep

294 ces of the respiratory, gastrointestinal and cervicovaginal tracts to efficiently reach the underlyin

295 mucosal surfaces of the gastrointestinal and cervicovaginal tracts, both of which are normally coated

296 ls of viral entry in the gastrointestinal or cervicovaginal tracts.

297 y switch for Mullerian duct epithelium to be cervicovaginal versus uterine.

298 Intravaginal HPV prime/boost reduced cervicovaginal viral titers 1,000-fold after intravagina

299 Cervicovaginal virome composition changes over time, par

300 Maternal blood, saliva, and cervicovaginal wash (CVW) samples were obtained.